Myriad Genetics, Inc. (NASDAQ:MYGN) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET
Company Participants
Matt Scalo – Senior Vice President of Investor Relations
Paul Diaz – President and Chief Executive Officer
Scott Leffler – Chief Financial Officer
Sam Raha – Chief Operating Officer
Mark Verratti – Chief Commercial Officer
Conference Call Participants
Douglas Schenkel – Wolfe Research
Puneet Souda – Leerink Partners
Prashant Kota – Goldman Sachs
Subu Nambi – Guggenheim Partners
Sung Ji Nam – Scotiabank
Rachel Vatnsdal – JPMorgan
Brandon Couillard – Wells Fargo
Tycho Peterson – Jefferies
Kyle Boucher – TD Cowen
John Kim – Bank of America
Operator
Good afternoon, and welcome to the Myriad Genetics Third Quarter 2024 Financial Earnings. I am Franz, and I’ll be the operator assisting you today. All lines have been placed on mute to prevent any background noise. After the speaker’s remarks, there will be a question-and-answer session [Operator Instructions]. Thank you.
And I would like to turn the call over to Matt Scalo. Please go ahead.
Matt Scalo
Thank you, Franz, and good afternoon, and welcome to the Myriad Genetics third quarter 2024 earnings call.
During the call, we will review financial results we released today. And afterwards, we will host a question-and-answer session. Our quarterly earnings release was issued this afternoon on Form 8-K and can be found on our website at investor.myriad.com.
I’m Matt Scalo, Senior Vice President of Investor Relations. And on the call with me today are Paul Diaz, our President and Chief Executive Officer; Scott Leffler, our Chief Financial Officer; Sam Raha, our Chief Operating Officer; and Mark Verratti, our Chief Commercial Officer.
This call can be heard live via webcast at investor.meriad.com, and a recording will be archived in the Investors section of our website, along with the slide presentation.
Read the full article here